Key result
Canagliflozin reduced the risk of major cardiovascular events by 20% compared to placebo in patients with type 2 diabetes mellitus and chronic kidney disease, with consistent benefits regardless of prior cardiovascular disease history.
Why the study?
Effects of canagliflozin on specific cardiovascular outcomes and in patients without previous cardiovascular disease (primary prevention) were uncertain.
Does canagliflozin reduce major cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease in both primary and secondary prevention groups?
RCT (n=4,401)
Double-blind
1:1
Yes
Does canagliflozin reduce major cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease in both primary and secondary prevention groups?
Canagliflozin reduces major cardiovascular events in patients with type 2 diabetes and chronic kidney disease, with consistent benefits observed regardless of prior cardiovascular disease status.
Answers are grounded in this paper and cite their sources.
Supports canagliflozin for MACE reduction even without prior CVD in T2DM and CKD; challenges meta-analyses limiting SGLT2i benefit to secondary prevention.
BACKGROUND: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). METHODS: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. RESULTS: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). CONCLUSIONS: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02065791.
No takes yet. Share an insight, caveat, or question.
Mahaffey et al. (2019) conducted an RCT in Type 2 diabetes mellitus and chronic kidney disease (n=4,401). Canagliflozin vs. Placebo was evaluated on Major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) (HR 0.80, 95% CI 0.67-0.95, p=0.01). Canagliflozin reduced the risk of major cardiovascular events by 20% compared to placebo in patients with type 2 diabetes mellitus and chronic kidney disease, with consistent benefits regardless of prior cardiovascular disease history.
Synapse has enriched 10 related papers. Consider them for comparative context: